Patent intelligence · US
US 9138479
Formulations for the treatment of diabetes
Formulations for the treatment of diabetes
Patent details — US 9138479
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 22, 2015
- Expiration
- Sep 17, 2035
- Applicant
- XERIS PHARMACEUTICALS, INC.
- Claims
- 34
- CPC classes
- A61K, A61K38/22, A61K38/28, A61K47/20
Quick answer
US 9138479 (Formulations for the treatment of diabetes) is held by XERIS PHARMACEUTICALS, INC.. Status: granted. Granted Sep 22, 2015. Expires Sep 17, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- XERIS PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 34
- CPC classes
- A61K, A61K38/22, A61K38/28, A61K47/20, A61K9/0019, A61K9/145
More from XERIS PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12377096
Methods of treating disease with levoketoconazole
granted -
US 11964003
Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
granted -
US 11957736
Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
granted -
US 11833157
Precipitation resistant small molecule drug formulations
granted -
US 11590205
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
granted -
US 11576951
Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
granted -
US 11446310
Stable formulations for parenteral injection of small molecule drugs
granted -
US 11129940
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
granted
Frequently asked questions
What is US patent 9138479?
US 9138479 (Formulations for the treatment of diabetes) is held by XERIS PHARMACEUTICALS, INC.. Status: granted. Granted Sep 22, 2015. Expires Sep 17, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9138479?
XERIS PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 9138479 expire?
Our index shows an expiration date of Sep 17, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.